Abbott LaboratoriesvsOmeros

ABT and OMER stock compared: price, dividend, valuation and results, from SEC filings.

ABT

Abbott Laboratories

$104.48

Value $182B

-0.22%
ABT's page

Abbott Laboratories (ABT) has a market value of $182B and Omeros (OMER) $1.0B. Over the last year, with dividends, ABT moved -17.7% and OMER +60.2%. The P/E is 38.6 for ABT and 10.7 for OMER. Dividend yield: ABT 2.41%, OMER none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    ABT$182B

    OMER$1.0B

    ABT is 173 times OMER

  • Revenue, 12 months

    ABT$48.2B

    OMER–

  • Net income, 12 months

    ABT$4.7B

    OMER$98M

    ABT is 48 times OMER

  • Operating margin

    ABT13.8%

    OMER–

  • ROIC

    ABT6.3%

    OMER–

  • P/E

    ABT38.6

    OMER10.7

    ABT is 3.6 times OMER

  • Dividend yield

    ABT2.4%

    OMER0.0%

    2.4 points apart

  • 5-year return

    ABT-10.3%

    OMER+85.1%

    95.4 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

ABT-10.3%

OMER+85.1%

010020020222023202420252026
Returns by period
PeriodABTWith dividendsOMERWith dividends
1 year since November 17, 2025-17.7%Price -19.6%+60.2%Price +60.2%
3 years since November 17, 2023+11.8%+3.8% a yearPrice +5.0%+787.2%+107.0% a yearPrice +787.2%
5 years since November 17, 2021-10.3%-2.1% a yearPrice -18.8%+85.1%+13.1% a yearPrice +85.1%
10 years since November 18, 2016+216.4%+12.2% a yearPrice +162.2%+11.3%+1.1% a yearPrice +11.3%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

ABTAbbott LaboratoriesOMEROmeros

Valuation

ABTOMER
Valuation
Price$104.48$14.55
Market value$182B$1.0B
Enterprise value (EV)$208B–
P/E38.610.7
P/E, 5-year median33.7–
P/B3.6–
EV/EBIT31.4–
Free cash flow yield3.7%–

Results and growth

ABTOMER
Results and growth
Revenue, 12 months$48.2B–
Net income, 12 months$4.7B$98M
Free cash flow, 12 months$6.8B-$37M
Earnings per share, 12 months$2.69$1.37
Revenue growth, year on year5.7%-34.0%
Revenue growth a year, past+5.1%over 5 years+15.4%over 4 years
EPS growth a year, past+8.3%over 5 years–

Margins and returns on capital

ABTOMER
Margins and returns on capital
Gross margin56.9%–
Operating margin13.8%–
Net margin9.8%–
ROIC6.3%–
ROE9.1%–

Balance sheet

ABTOMER
Balance sheet
Cash$4.3B$95M
Total debt$31.2B–
Net debt / EBITDA3.3–
Interest cover6.7×-4.3×

Dividends and buybacks

ABTOMER
Dividends and buybacks
Dividend yield2.4%–
Dividend per share, 12 months$2.52–
Dividend growth a year, past+10.4%over 5 years–
Buyback yield0.5%–
Shareholder yield2.9%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: ABT or OMER

Didn't find what you were looking for?

Ask us
Which is bigger, Abbott Laboratories or Omeros?

By market value, Abbott Laboratories ($182B) is about 173.3 times Omeros ($1.0B), at today's prices.

How did ABT and OMER stock do over the last 10 years?

Since November 18, 2016, ABT's price moved +162.2% and OMER's +11.3%. With dividends: ABT +216.4% (+12.2% a year), OMER +11.3% (+1.1% a year). Past returns do not predict future ones.

Which pays the higher dividend, ABT or OMER?

The dividend yield at today's price is 2.41% for Abbott Laboratories and none for Omeros. Over the last twelve months they paid $2.52 and – per share.

What is the P/E of ABT and OMER?

At today's price, the P/E is 38.6 for ABT and 10.7 for OMER. It is the share price over the last twelve months' earnings per share.

Which is the better investment, Abbott Laboratories or Omeros?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.